MedTrace Logo

A Double-Blind Study of E5555 in Japanese Subjects With Coronary Artery Disease

NCT00540670 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2013-05-13

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of E5555 in Japanese subjects with coronary artery disease.

Conditions

Interventions

DRUG

E5555 50 mg

E5555 50 mg (tablet) taken orally, once a day.

DRUG

E5555 100 mg

E5555 100 mg (tablet) taken orally, once a day.

DRUG

E5555 200 mg

E5555 200 mg (tablet) taken orally, once a day.

DRUG

Placebo

Placebo (tablet) taken orally, once a day.

Sponsors & Collaborators

  • Eisai Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Masaru Takeuchi · New Product Development, Clinical Research Center, Eisai Co., Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00540670 on ClinicalTrials.gov